Genistein crystalline - Axcentua

Drug Profile

Genistein crystalline - Axcentua

Alternative Names: AXP-107 11; genistein sodium salt dihydrate; genistein-SSDH

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axcentua Pharmaceuticals
  • Class Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA topoisomerase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer
  • Preclinical Mucopolysaccharidosis III
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Sweden (PO, Capsule)
  • 15 Mar 2016 Biomarkers information updated
  • 25 Sep 2015 Phase-I/II development for Pancreatic cancer is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top